IP Library Granted Patent US 12,138,305
Granted Patent B2
US 12,138,305 · App. 17/705,837 · Granted Nov 12, 2024

Nucleoside-modified RNA for inducing an adaptive immune response

Inventors: Drew Weissman (Wynnewood, PA); Norbert Pardi (Philadelphia, PA)
Assignee: The Trustees of the University of Pennsylvania
A61K39/12A61K9/0019A61K9/127A61K31/7115A61K31/712A61K39/0011A61K39/002A61K39/02A61K39/145A61P31/16A61P31/18C07C219/08C07D295/13C12N15/11A61K2039/51A61K2039/55555A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,138,305
App. No.
17/705,837
Granted
Nov 12, 2024
Kind
B2
Abstract

The present invention relates to compositions and methods for inducing an adaptive immune response in a subject. In certain embodiments, the present invention provides a composition comprising a nucleoside-modified nucleic acid molecule encoding an antigen, adjuvant, or a combination thereof. For example, in certain embodiments, the composition comprises a vaccine comprising a nucleoside-modified nucleic acid molecule encoding an antigen, adjuvant, or a combination thereof.

Claims (13)

1. A composition for inducing an adaptive immune response in a subject, the composition comprising at least one nucleoside-modified RNA encoding at least one influenza hemagglutinin (HA) antigen, wherein the mRNA molecule encoding the influenza antigen comprises a sequence selected from SEQ ID NO:5 and SEQ ID NO:8.

2. The composition of claim 1 , wherein the at least one isolated nucleoside-modified RNA comprises pseudouridine.

3. The composition of claim 1 , wherein the at least one isolated nucleoside-modified RNA comprises 1-methyl-pseudouridine.

4. The composition of claim 1 , wherein the composition further comprises an adjuvant.

5. The composition of claim 1 , wherein the at least one nucleoside-modified RNA further encodes at least one adjuvant.

6. The composition of claim 1 , further comprising a lipid nanoparticle (LNP).

7. The composition of claim 6 , wherein the at least one nucleoside-modified RNA is encapsulated within the LNP.

8. The composition of claim 1 , wherein the composition is a vaccine.

9. A method of inducing an adaptive immune response in a subject comprising administering to the subject an effective amount of the composition of claim 1 .

10. The method of claim 9 , wherein the composition is administered by a delivery route selected from the group consisting of intradermal, subcutaneous, and intramuscular.

11. The method of claim 9 , wherein the method comprises a single administration of the composition.

12. The method of claim 9 , wherein the method comprises a multiple administrations of the composition.

13. The method of claim 9 , wherein the method treats an influenza infection.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 19, 2023
From: WEISSMAN, DREW; PARDI, NORBERT
To: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Reel/Frame 062419/0592 →
Continuity (3)
Continuation 15569546
Provisional Application 62153143 · Apr 27, 2015
Related Publication 20220226461A1 · Jul 21, 2022
Cited By (3)
US 12,667,627 US 12,678,515 US 12,714,670